Spinal myoclonus following intrathecal administration of diatrizoate meglumine.
Life-threatening myoclonus developed in a patient following inadvertent intrathecal usage of 60% diatrizoate meglumine. Rhabdomyolysis and myoglobinuria occurred. The patient was successfully treated with midazolam and vecuronium and complete recovery occurred.
Sam
M C
MC
Department of Neurology, Robert C. Byrd Health Sciences Center, West Virginia University, USA.
Gutmann
L
L
D000368:Aged; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects*; D003974:Diatrizoate Meglumine / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D007278:Injections, Spinal; D008297:Male; D008874:Midazolam / Q000627:therapeutic use; D009207:Myoclonus / Q000139:chemically induced* / Q000188:drug therapy; D009212:Myoglobinuria / Q000139:chemically induced; D003473:Neuromuscular Nondepolarizing Agents / Q000627:therapeutic use; D012206:Rhabdomyolysis / Q000139:chemically induced; D013118:Spinal Cord Diseases / Q000139:chemically induced* / Q000188:drug therapy; D014673:Vecuronium Bromide / Q000627:therapeutic use
D003287:Contrast Media; D006993:Hypnotics and Sedatives; D003473:Neuromuscular Nondepolarizing Agents; D003974:Diatrizoate Meglumine; D014673:Vecuronium Bromide; D008874:Midazolam